2024 annual financial data
Alnylam Pharmaceuticals 2024 Net income growth
Direct answer
Net income growth was 36.82%.
Operating income was -176,885,000 USD and net income was -278,157,000 USD.
Operating cash flow was -8,312,000 USD.
Get free Alnylam Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,248,243,000 USD
- Operating income
- -176,885,000 USD
- Net income
- -278,157,000 USD
- Operating cash flow
- -8,312,000 USD